Consider Eurofins DiscoverX’s custom development capabilities for custom cell lines, assays, & enzyme development.
Cell-based potency assays are critical tools to measure the efficacy of a drug during stability and potency testing. Potency assays are initiated in the early drug development stage to measure the biologic therapeutic's intended biological effect and mechanism of action (MOA) being analyzed. Quality control (QC) lot-release testing, intended for late-stage drug release programs, involves assays that ensure consistency with high lot-to-lot reproducibility. Given that the process of drug discovery and development is time consuming, complex, and expensive, implementing a physiologically relevant assay platform from the early development phase to late-stage drug release programs such as QC lot release can prove to be highly valuable.
Eurofins DiscoverX® develops qualified, MOA-reflective cell-based assays (bioassays) that are phase-appropriate and meet the requirements of specific therapeutic development stages, including potency and QC lot-release testing. These bioassays are derived from stable cell lines and provide a simple, thaw-and-use approach that alleviates assay passage-to-passage variability associated with cells derived from continuous cell culture. Packaged with ready-to-use cryopreserved cells, plates, and all the reagents and documents needed, Eurofins DiscoverX bioassay kits offer the ideal solution for your therapeutic development programs. These kits are rigorously tested to meet ICH (International Council for Harmonization) requirement guidelines and qualified with marketed biologic drugs or reference standards, allowing you to confidently de-risk your potency testing program and accelerate your therapeutic development timelines.
Consider Eurofins DiscoverX’s custom development capabilities for custom cell lines, assays, & enzyme development.
| Eurofins DiscoverX | CRO/CDMO Site | |||
|---|---|---|---|---|
| Stable Cell Lines > | Ready-to-use Bioassay Format > | Qualified Method with Marketed Drug > | Assay Transfer Support to CRO/CDMO Site > | Assay Validation for GMP Lot Release Testing > |
|
|
ICH-Based Assay Qualification
|
|
|
Eurofins DiscoverX offers the largest portfolio of cell-based assays for characterization studies, potency testing in QC lot-release, neutralizing antibodies (NAbs) detection, and stability programs. Cell-based bioassay kits are easy to implement in any lab from pre-clinical development to QC lot release, and qualified with marketed biologic drugs or reference standards. Global technical support and field application scientist teams provide end-to-end assay transfer support for you at contract research and contract development and manufacturing organizations (CRO/CDMO). GMP = good manufacturing practices.

Eurofins DiscoverX bioassays are fit-for-purpose for implementation in QC lot-release for potency testing, helping to accelerate the time-to-market for therapeutics by 6 to 9 months, and ensuring high lot-to-lot reproducibility and accuracy for the life of the program. These assays can be readily transferred and implemented in potency and stability programs that typically happen under GMP conditions at the sponsors’ testing sites or partner CRO/CDMO sites. Access off-the-shelf bioassay kits that have been successfully implemented in 100+ global programs covering popular and unique druggable target classes. NA = North America, EU = Europe, APAC = Asia Pacific, and NAb = Neutralizing Antibody.

Confidently expedite regulatory approval of your drug candidates while ensuring consistency and comparability in their evaluation across different regulatory jurisdictions, facilitating global drug development efforts.